Eli Lilly and Company (LLY) Up 4.7% — Should I Build a Stake Now?
Eli Lilly and Company (LLY) surged 4.68% on Wednesday, adding $57.36 to close at $1,283.09 on the NYSE in a session that underscored the conviction buyers have been building in this name. The move carries particular significance because it pushed LLY decisively above its 52-week high of $1,249.45, set on July 7, 2026 — a breakout that clears overhead resistance and opens the chart to price discovery at levels the stock has not previously visited.
Trading volume came in at approximately 1.47 million shares, well below the 90-day average of roughly 3.06 million. The lighter participation alongside a move of this magnitude points to a demand-driven session with little in the way of speculative noise — buyers were motivated, and sellers were scarce.
Why Eli Lilly and Company Price is Moving Higher
The catalyst behind today's move is unambiguous: Eli Lilly delivered one of its most decisive earnings beats in recent history when it reported Q2 results on August 5, 2026. Non-GAAP EPS came in at $8.38 against a consensus estimate of $6.06 — a $2.32 beat that left little room for skeptics to argue the quarter was a near-miss. Revenue of $22.97 billion exceeded expectations by $2.28 billion, with the top line expanding 47.7% year over year from $15.56 billion. Gross margin expanded to 85.8% from 84.3% a year earlier, while net income on a reported basis grew 25% to $7.10 billion. These are not incremental improvements — they represent a step-change in Lilly's earnings profile that the market is still repricing.
The engine powering those numbers is the GLP-1 franchise. Mounjaro sales jumped 91% year over year to $9.94 billion in the quarter, and Zepbound revenue rose 46% to $4.93 billion — two products collectively generating nearly $15 billion in a single quarter. Management responded to that demand signal by raising 2026 revenue guidance to $85 billion–$87 billion from the prior $82 billion–$85 billion range and lifting the performance-margin forecast to 49.0%–50.5% from 47.0%–48.5%. Adjusted EPS guidance was set at $35.50–$36.50, a modest tightening of the prior $35.50–$37.00 range that reflects $2.8 billion in acquired research charges — a near-term accounting drag, not an operational deterioration.
Looking further out, the pipeline adds another layer of conviction. Positive Phase 3 data for retatrutide were reported alongside the Q2 results, with an FDA filing now planned for Q1 2027. That timeline keeps the obesity-drug story squarely in focus and gives investors a credible next catalyst to anchor forward expectations. Peer data was not available for direct session comparison, but within the Health Care universe, Lilly's combination of top-line velocity, margin expansion, and pipeline depth distinguishes it from the broader group.
What is the Eli Lilly and Company Rating - Should I Buy?
Weiss Ratings assigns LLY a B- rating. Current recommendation is Buy.
The fundamental data backing that assessment is compelling across multiple dimensions. Revenue growth of 47.67% earns the Excellent Growth Index — an extraordinary pace for a company already operating at trillion-dollar market cap scale, where maintaining that kind of velocity typically requires dominant positioning in large and expanding markets. The 33.52% profit margin reinforces the Excellent Growth Index with evidence that Lilly is not sacrificing economics to chase volume; the business is growing fast and keeping a substantial share of every dollar. ROE of 102.29% earns the Excellent Efficiency Index — a figure that reflects the capital-light, IP-driven nature of pharmaceutical leadership, where proprietary drug formulations and manufacturing scale allow earnings to compound well in excess of the equity invested to generate them. The Excellent Solvency Index rounds out the quality picture, indicating the balance sheet can support continued investment in R&D and acquisitions without undue financial stress.
The Good Total Return Index suggests performance has been meaningful over time, while the Fair Volatility Index serves as a relevant caution: at $1,283 per share, LLY moves in absolute dollar terms that can unsettle shorter-horizon investors. A forward P/E of 41.13 reflects elevated market expectations and sets a high bar — the stock is priced for continued execution, and any stumble in Mounjaro or Zepbound demand trends would be quickly penalized. The $2.8 billion in acquired research charges already baked into guidance are worth monitoring as the company integrates external assets into its pipeline.
Within the Health Care sector, Eli Lilly holds the same rating as AbbVie Inc. (ABBV, B-) and Bristol-Myers Squibb Company (BMY, B-), while Johnson & Johnson (JNJ, B), Amgen Inc. (AMGN, B), and Vertex Pharmaceuticals Incorporated (VRTX, B) carry the full-step B. The B- reflects a profile where the growth and efficiency case is strong but volatility and valuation demand respect — investors buying here are paying a premium for one of the most powerful drug franchises in the world, and the B- rating acknowledges both the opportunity and the risk that comes with that price.
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a Health Care company with a research-driven model built around discovering, developing, and commercializing medicines for some of medicine's most persistent and large-scale conditions. The company's commercial portfolio spans diabetes, obesity, oncology, immunology, and neuroscience — therapeutic categories where patient populations are large, treatment cycles are long, and brand loyalty among prescribers runs deep. Lilly's strength lies in its ability to move candidates from discovery through late-stage trials and onto pharmacy shelves with a hit rate that has historically outpaced most peers.
The centerpiece of Lilly's current commercial story is its GLP-1 receptor agonist platform. Mounjaro and Zepbound have established Lilly as a dominant force in the metabolic disease space, with Mounjaro addressing type 2 diabetes and Zepbound targeting obesity — two indications with enormous global prevalence and chronically under-penetrated treatment rates. The scale of demand for both products has required substantial investment in manufacturing capacity, and Lilly has committed billions to expanding production infrastructure to meet a volume trajectory that continues to accelerate. Retatrutide, the next-generation candidate now headed toward an FDA filing in Q1 2027, represents the company's effort to extend that platform advantage before competitors can close the clinical gap.
Beyond the GLP-1 franchise, Lilly's oncology and immunology portfolios provide diversification and additional growth runways. Its intellectual property portfolio, global manufacturing footprint, and relationships with large payer and hospital systems create competitive advantages that are not quickly replicated. The company's consistent investment in early-stage research — including through acquisitions that bring external innovation in-house — reflects a business model designed to sustain commercial relevance across multiple product generations rather than relying on a single blockbuster cycle.
Investor Outlook
Eli Lilly and Company (LLY) carries a Weiss Rating of B- (Buy), and today's breakout above the prior 52-week high positions the stock at a technically significant juncture heading into the second half of 2026. Investors will want to track Mounjaro and Zepbound demand trends in subsequent quarters, monitor progress on the retatrutide FDA filing, and watch whether management's raised guidance proves conservative or fully priced in as the year progresses. See full rankings of all B--rated Health Care stocks inside the Weiss Stock Screener.
--